| For: |
Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK. |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i41/6401.htm |
| Number | Citing Articles |
| 1 |
Seong Hyun Jeong, Jae Ho Han, Jang Hee Kim, Mi Sun Ahn, Yoon Ho Hwang, Hyun Woo Lee, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Kwang Jae Lee, Seung Soo Sheen, Ho-Yeong Lim. Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy. Digestive Diseases and Sciences 2011; 56(1) doi: 10.1007/s10620-010-1280-8
|
| 2 |
Shishir K. Maithel, Ipek Coban, Peter J. Kneuertz, David A. Kooby, Bassel F. El-Rayes, John S. Kauh, Juan Sarmiento, Charles A. Staley, N. Volkan Adsay. Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection. Annals of Surgical Oncology 2011; 18(9) doi: 10.1245/s10434-011-1610-x
|
| 3 |
Nurgül Yaşar. Evaluation of the Effect of ERCC1 Expression on Survival and Treatment Response in Patients with Advanced Gastric Cancer. Turkish Journal of Health Science and Life 2026; 9 doi: 10.56150/tjhsl.1779623
|
| 4 |
V. Formica, E. Doldo, F.R. Antonetti, A. Nardecchia, P. Ferroni, S. Riondino, C. Morelli, H.T. Arkenau, F. Guadagni, A. Orlandi, M. Roselli. Biological and predictive role of ERCC1 polymorphisms in cancer. Critical Reviews in Oncology/Hematology 2017; 111 doi: 10.1016/j.critrevonc.2017.01.016
|
| 5 |
Nayiri M Kaissarian, Douglas Meyer, Chava Kimchi-Sarfaty. Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes. JNCI: Journal of the National Cancer Institute 2022; 114(8) doi: 10.1093/jnci/djac090
|
| 6 |
PENG SONG, QIN YIN, MING LU, BO FU, BAOLIN WANG, QINGHONG ZHAO. Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis. Experimental and Therapeutic Medicine 2015; 9(4) doi: 10.3892/etm.2015.2284
|
| 7 |
Edwin P. Hui, Brigette B. Y. Ma, K. C. Allen Chan, Charles M. L. Chan, Cesar S. C. Wong, Ka Fai To, Anthony W. H. Chan, Stewart Y. Tung, Wai‐Tong Ng, Ashley C. Cheng, Victor H. F. Lee, Stephen L. Chan, Herbert H. F. Loong, Michael K. M. Kam, Sing‐Fai Leung, Rosalie Ho, Frankie Mo, Roger K. C. Ngan, Anthony T. C. Chan. Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer 2015; 121(16) doi: 10.1002/cncr.29413
|
| 8 |
Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis. Tumor Biology 2014; 35(9) doi: 10.1007/s13277-014-2128-1
|
| 9 |
Haiying Peng, Shaobo Yao, Qingyu Dong, Yanxia Zhang, Weihong Gong, Zhongyao Jia, Li Yan. Excision repair cross-complementing group 1 (ERCC1) overexpression inhibits cell apoptosis and is associated with unfavorable prognosis of esophageal squamous cell carcinoma. Medicine 2018; 97(31) doi: 10.1097/MD.0000000000011697
|
| 10 |
Aristotelis Bamias, M. Karina, P. Papakostas, I. Kostopoulos, M. Bobos, G. Vourli, E. Samantas, Ch. Christodoulou, G. Pentheroudakis, D. Pectasides, M. A. Dimopoulos, G. Fountzilas. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology 2010; 65(6) doi: 10.1007/s00280-010-1256-6
|
| 11 |
Lauren M. Postlewait, Cecilia G. Ethun, David A. Kooby, Juan M. Sarmiento, Zhengjia Chen, Charles A. Staley, Edith Brutcher, Volkan Adsay, Bassel El‐Rayes, Shishir K. Maithel. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Journal of Surgical Oncology 2016; 114(3) doi: 10.1002/jso.24317
|
| 12 |
Zhixin Cao, Xiangshang Xu, Xuelai Luo, Li Li, Bin Huang, Xiaolan Li, Deding Tao, Junbo Hu, Jianping Gong. Role of RANTES and its receptor in gastric cancer metastasis. Journal of Huazhong University of Science and Technology [Medical Sciences] 2011; 31(3) doi: 10.1007/s11596-011-0378-3
|
| 13 |
Marina Schena, Simonetta Guarrera, Lucio Buffoni, Angelica Salvadori, Floriana Voglino, Alessandra Allione, Giancarlo Pecorari, Enrico Ruffini, Paolo Garzino-Demo, Sara Bustreo, Lorena Consito, Paolo Bironzo, Giuseppe Matullo. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair 2012; 11(4) doi: 10.1016/j.dnarep.2012.01.003
|
| 14 |
Mladen V Tzvetkov, Gerrit Behrens, Valerie P O‘Brien, Karin Hohloch, Jürgen Brockmöller, Peter Benöhr.
Pharmacogenetic Analyses of Cisplatin-induced Nephrotoxicity Indicate a Renoprotective Effect of
ERCC1
Polymorphisms
. Pharmacogenomics 2011; 12(10) doi: 10.2217/pgs.11.93
|
| 15 |
Ralf Metzger, Elfriede Bollschweiler, Arnulf H Hölscher, Ute Warnecke-Eberz. ERCC1: Impact in Multimodality Treatment of Upper Gastrointestinal Cancer. Future Oncology 2010; 6(11) doi: 10.2217/fon.10.140
|
| 16 |
Rui Gao, Kelie M Reece, Tristan Sissung, Samuel H Fu, David J Venzon, Eddie Reed, Shawn D Spencer, Douglas K Price, William D Figg. Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?. BMJ Open 2013; 3(1) doi: 10.1136/bmjopen-2012-002030
|
| 17 |
Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou. Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology 2014; 140(12) doi: 10.1007/s00432-014-1758-4
|
| 18 |
Aristea Kalikaki, Alexandra Voutsina, Anastasios Koutsopoulos, Chara Papadaki, Maria Sfakianaki, Emmanouel Yachnakis, Alexandros Xyrafas, Athanasios Kotsakis, Sofia Agelaki, John Souglakos, Dimitrios Mavroudis, Vassilis Georgoulias. ERCC1SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Cancer Investigation 2015; 33(4) doi: 10.3109/07357907.2014.1001897
|
| 19 |
Mark S. Cohen, Mazin F. Al-kasspooles, Stephen K. Williamson, David Henry, Melinda Broward, Katherine F. Roby. Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo. Annals of Surgical Oncology 2010; 17(1) doi: 10.1245/s10434-009-0669-0
|
| 20 |
Leonor Benhaim, Melissa Janae LaBonte, Heinz-Josef Lenz. Pharmacogenomics and metastatic colorectal cancer: Current knowledge and perspectives. Scandinavian Journal of Gastroenterology 2012; 47(3) doi: 10.3109/00365521.2012.640832
|
| 21 |
Jingwei Liu, Caiyun He, Chengzhong Xing, Yuan Yuan. Nucleotide excision repair related gene polymorphisms and genetic susceptibility, chemotherapeutic sensitivity and prognosis of gastric cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 2014; 765 doi: 10.1016/j.mrfmmm.2014.04.008
|
| 22 |
Expression patterns and prognostic significances of RRM1 and ERCC1 in pancreatic carcinoma and cholangiocarcinoma. Indian Journal of Pathology and Microbiology 2021; 64(5) doi: 10.4103/IJPM.IJPM_537_19
|
| 23 |
Sharareh Mokmeli, Golnaz Asaadi Tehrani, Reza Eghdam Zamiri, Tayyeb Bahrami. Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention 2016; 17(3) doi: 10.7314/APJCP.2016.17.3.1369
|
| 24 |
Ming Yin, Jingrong Yan, Eva Martinez-Balibrea, Francesco Graziano, Heinz-Josef Lenz, Hyo-Jin Kim, Jacques Robert, Seock-Ah Im, Wei-Shu Wang, Marie-Christine Etienne-Grimaldi, Qingyi Wei.
ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis. Clinical Cancer Research 2011; 17(6) doi: 10.1158/1078-0432.CCR-10-2169
|
| 25 |
Xin Zhang, Li-Peng Jiang, Yu Yin, Ya-Di Wang. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumor Biology 2014; 35(6) doi: 10.1007/s13277-014-1746-y
|
| 26 |
Zhen Wang, Jun-qiang Chen, Jin-lu Liu, Xin-gan Qin, Yuan Huang. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterology 2012; 12(1) doi: 10.1186/1471-230X-12-137
|
| 27 |
WEI LI, ZHIGANG JIE, ZHENGRONG LI, YI LIU, QUAN GAN, YIQIU MAO, XUEMIN WANG. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. Molecular Medicine Reports 2014; 9(6) doi: 10.3892/mmr.2014.2112
|
| 28 |
Yan Wang, Jialong Li, Cheng Shen, Yanming Wu, Guowei Che. Clinical Role of Excision Repair Cross-Complementing 1 Gene Expression in Resected Esophageal Squamous Cell Carcinoma: A Meta-Analysis. Digestive Diseases and Sciences 2020; 65(8) doi: 10.1007/s10620-019-05941-8
|